PT Aurogen Pharma Indonesia

Committed to Quality and Safety

PT Aurogen Pharma Indonesia represents a significant milestone as a subsidiary of Aurobindo Pharma Limited, entering Indonesia's dynamic pharmaceutical landscape in 2023.

Established in 1986 in Hyderabad, Aurobindo Pharma Ltd. has built an impressive reputation in the global pharmaceutical industry with an ambitious vision to achieve recognition among the world's top 25 pharmaceutical companies by 2030. Its mission centers on becoming a globally trusted pharmaceutical partner through continuous innovation, research excellence, and the development of high-quality pharmaceutical solutions.

Aurobindo Pharma Ltd. demonstrates its commitment to global healthcare by developing, manufacturing, and distributing an extensive portfolio of pharmaceutical products including generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectable medications - all manufactured to meet only the most stringent international regulatory standards. With a robust global presence spanning over 150 countries, Aurobindo continues to strengthen its position as a reliable partner in the worldwide pharmaceutical community.

60bn+

Formulation
manufacturing
capacity in FY25

30

Manufacturing
facilities globally

18 Formulations 13 API

09

R&D Centers

5 in India
4 in US

40,000+

Global
workforce**

#1

Largest Generic Pharma Company in the US
(by Rx dispensed)*

#3

Largest listed Indian Pharma Company
(by FY25 revenue from operations)

#10

Ranks amongst the top 10 Generic companies in 8 countries of Europe

150+

Countries with export presence
(in FY24)

Aurobindo Pharma Limited is the number 1 pharmaceutical company in the United States that produces generic products.

(based on IQVIA Dec’24 data)

Aurobindo Pharma Limited has 30 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK, MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.

PT Aurogen Pharma Indonesia

Following significant move of acquisition of Pfizer Indonesia – Upjohn division, PT Aurogen Pharma Indonesia commencing its operation on Dec 15th 2023. With commitment and focus on improving patient outcomes and advancing medical science, PT Aurogen Pharma Indonesia poised to make substantial contribution to Indonesia healthcare landscape through focused therapeutic area such as cardiovascular, pain, central-nervous-system, men's health, and other.

Contact Us